20/20 BIOLABS, INC.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0M | $1.8M |
| Cost of Revenue | $1.4M | $1.4M |
| Gross Profit | $604.5K | $360.3K |
| Gross Margin | 29.6% | 20.6% |
| Operating Expenses | ||
| Research & Development | $592.6K | $1.3M |
| SG&A Expense | $3.3M | $4.8M |
| Operating Income | $-3.3M | $-5.7M |
| Operating Margin | -162.9% | -324.0% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-3.7M | $-5.6M |
| Net Margin | -182.8% | -316.8% |
| EPS (Basic) | $-0.76 | $-1.16 |
| EPS (Diluted) | $-0.76 | $-1.16 |
| Shares Outstanding (Basic) | 4.9M | 4.8M |
| Shares Outstanding (Diluted) | 4.9M | 4.8M |
| Dividends Per Share | — | — |